The ability to quantify Aqp2 expression via GFP fluorescence in a scalable format makes this system ideal for: 1) drug screening to identify small molecules that can either enhance Aqp2 expression (e.g., for certain forms of Nephrogenic Diabetes Insipidus, NDI) or suppress it; 2) CRISPR-mediated functional screens (e.g., using CRISPRa/i or knockouts) targeting specific gene families, such as kinases or transcription factors, to systematically map both positive and negative regulators of Aqp2 transcription. The gene discussed is AQP2; the disease is nephrogenic diabetes insipidus.